1-7 of 7
Xinglu Zhou
Close
Sort by
Journal Articles

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Dual CK1ε/PI3Kδ Inhibitor HZ-H08905 in Adult Patients with Relapsed and/or Refractory Hematologic Malignancies

Juying Wei, Wenjuan Yu, Zhengming Jin, Keshu Zhou, Haiyan Yang, Fei Li, Lanfang Li, Miao Hu, Xinglu Zhou, Jie Jin
Journal: Blood
Blood (2023) 142 (Supplement 1): 4428.
https://doi.org/10.1182/blood-2023-185363
Published: 2023
Journal Articles

A Phase I/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BTK Inhibitor HZ-a-018 in Adult Patients with Relapsed and/or Refractory Central Nervous System Lymphoma

Wenbin Li, Zhuang Kang, Feng Chen, Shenglan Li, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xinglu Zhou
Journal: Blood
Blood (2023) 142 (Supplement 1): 3139.
https://doi.org/10.1182/blood-2023-185241
Published: 2023
Journal Articles

Discovery of HZ-L105, a Next Generation of Bcl-2 Inhibitor, Overcomes Bcl-2 Mutation and Exhibits Superior Antitumor Activity

Xingguo Liu, Yang Lou, Yizhe Wu, Mingbo Su, Anhui Gao, Jinglai Huang, Haiyan Yang, Li Zhong, Xinglu Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 7798–7799.
https://doi.org/10.1182/blood-2022-166997
Published: 2022
Journal Articles

Discovery and Preclinical Study of Novel BTK Degrader HZ-Q1060

Xingguo Liu, Yubo Zhou, Yizhe Wu, Xiaomin Luo, Jiangfeng Xie, Xinxin Jin, Haiyan Yang, Li Jia, Xinglu Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 4942.
https://doi.org/10.1182/blood-2022-167308
Published: 2022
Journal Articles

Dual CK1ε/PI3Kδ Inhibitor HZ-H08905, Exhibits As a Potential Therapeutic Strategy for Hematologic Malignancies

Juying Wei, Wenjuan Yu, Hongyan Tong, Min Yang, Miao Hu, Xingguo Liu, Yizhe Wu, Xinglu Zhou, Jie Jin
Journal: Blood
Blood (2022) 140 (Supplement 1): 12065.
https://doi.org/10.1182/blood-2022-165195
Published: 2022
Journal Articles

HZ-a-018 Is a Highly Selective and Potent BTK Inhibitor with CNS-Penetrating Profile for Central Nervous System Lymphoma

Zhuang Kang, Feng Chen, Yi Lin, Xianggui Yuan, Xi Chen, Wenbin Qian, Haiyan Yang, Miao Hu, Xingguo Liu, Xinglu Zhou, Wenbin Li
Journal: Blood
Blood (2022) 140 (Supplement 1): 12064.
https://doi.org/10.1182/blood-2022-166776
Published: 2022
Journal Articles

HZ-R061, a Selective STAT3 Degrader with Activity in Preclinical Model of Hematologic Malignances

Yizhe Wu, Xingguo Liu, Xinxin Jin, Jiangfeng Xie, Haiyan Yang, Xinglu Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 7818.
https://doi.org/10.1182/blood-2022-167261
Published: 2022